Prediction markets tracking the federal rescheduling of marijuana saw a sharp, positive repricing on Wednesday, April 22, 2026, as all contracts moved toward a significantly accelerated timeline. The shift was driven by multiple media reports, citing administration officials, that the Department of Justice (DOJ) was preparing to finalize the reclassification of cannabis from Schedule I to Schedule III as soon as that day. The most significant move occurred in the shortest-dated contract, "Before July 2026," which surged 16 percentage points to 41% on massive volume, signaling a dramatic shift in consensus toward imminent action.
Distribution Analysis
The across-the-board increase in probabilities indicates a strong, unified market reaction. The repricing was not a simple reallocation of probability between different timeframes but rather a wholesale increase in the perceived likelihood of rescheduling happening soon. Contracts for every timeframe, from mid-2026 to early 2029, saw double-digit or near double-digit gains.
| Outcome | Current Prob | Change | Volume |
|---|---|---|---|
| Before July 2026 | 41% | +16.0pp | 242,320 |
| Before 2027 | 67% | +19.0pp | 58,243 |
| Before 2028 | 83% | +14.0pp | 14,021 |
| Before Jan 20, 2029 | 88% | +7.0pp | 11,769 |
Net: All 4 active contracts rose on combined volume of over 326,000, shifting the implied timeline for rescheduling significantly sooner.
What's Driving the Shift
The market's sudden re-evaluation appears to be a direct response to new information suggesting a long-stalled administrative process is about to conclude.
Reports of Imminent DOJ Action: The primary catalyst was a series of reports from outlets including Axios, citing administration sources, that the DOJ could officially move to reschedule marijuana as a Schedule III drug as soon as Wednesday, April 22 [2, 3, 4]. This would mark the culmination of a process initiated under the previous administration and accelerated by a December 2025 executive order from President Trump [9].
Presidential Impetus: The news follows recent public comments from President Trump complaining that the DOJ was "slow-walking" his directive to complete the rescheduling "in the most expeditious manner" [5]. This high-level pressure likely contributed to the DOJ's move to finalize the rule after months of perceived inaction.
Breaking the Administrative Logjam: Until this week, the rescheduling process appeared mired in bureaucratic delays. The Drug Enforcement Administration (DEA) had a pending interlocutory appeal regarding the hearing process, and the retirement of its sole Administrative Law Judge had left proceedings in a state of paralysis [1, 7, 10]. The new reports suggest the White House and DOJ intend to bypass or resolve this deadlock to execute the president's order.
Market Context
Reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act is not full federal legalization. However, it represents a landmark shift in U.S. drug policy. A Schedule I classification signifies a drug has "no currently accepted medical use and a high potential for abuse," placing it alongside substances like heroin [3]. Moving it to Schedule III would be an official federal recognition of its medical value and would place it in a category with drugs like ketamine and Tylenol with codeine [3, 8].
For the state-legal cannabis industry, the most significant impact would be the elimination of IRC Section 280E, a tax provision that prevents businesses handling Schedule I or II substances from taking standard business deductions [3, 10]. This has resulted in effective tax rates of 60% or higher, and its removal would dramatically improve the financial viability of these companies. The market's high-volume surge, particularly in the contract for action before July 2026, indicates traders are pricing in a high probability that this regulatory relief is just weeks away.
What to Watch
The key development to watch for is the official announcement from the Department of Justice and the publication of the final rule in the Federal Register. The timing of this publication will determine the resolution of the most imminent market contracts. While rescheduling appears likely, the process could still face legal challenges from anti-rescheduling groups, who have previously stated their intent to sue to block the move [1]. The market will resolve based on reporting from a slate of national news outlets, including the Associated Press, Reuters, and The New York Times.
